Phase 3
Completed N=2,452
A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)
Source: ClinicalTrials.gov NCT00046228 ↗Enrolled (actual)
2,452
Serious AEs
21.4%
Results posted
May 2009
Primary outcomePrimary: The Composite of All-Cause Mortality or Complications of MI at 90 Days. — 86; 86; 81 participants — p=0.551
Summary
The purpose of this study is to determine whether abciximab given in combination with reteplase, before patients have a coronary intervention (a standard treatment where a catheter is inserted into the heart artery to get blood flowing past the clot), is safe and effective in the treatment of heart attacks compared to only abciximab given during coronary intervention.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Composite of All-Cause Mortality or Complications of MI at 90 Days. |
86; 86; 81 | 0.551 |
| SECONDARY Complications of MI as Defined in the Primary Outcome Measure Through 90 Days |
72; 61; 61 | 0.247 |
| SECONDARY All-Cause Mortality Through 90 Days |
36; 45; 43 | 0.494 |
| SECONDARY Subjects With ST-Segment Resolution > 70% From Baseline at 60 to 90 Minutes Following Randomization |
75; 85; 108 | 0.016 sig |
| SECONDARY All-Cause Mortality Through 1 Year |
56; 60; 52 | 0.603 |
Eligibility Criteria
Inclusion Criteria
- Patients who have prolonged, continuous (lasting at least 20 minutes) signs and symptoms of A heart attack not eliminated with nitrates and onset within 6 hours of randomization,and confirmation by Electrocardiogram
Exclusion Criteria
- Low risk clinical presentation
- patients who will not be undergoing a catherization within 4 hours of the qualifying Electrocardiogram
Data sourced from ClinicalTrials.gov (NCT00046228). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.